London, UK, 8 November 2021 – Abingworth, a leading international life sciences investor, today announced the further strengthening of its investment team with the appointment of Jayson Punwani, PhD, MBA as Partner. Jayson will be based at the firm’s Menlo Park, CA office. He will work with the transatlantic team across all locations, actively seeking new opportunities and supporting existing investments in innovative private and public companies, at all stages of development, as well as those focused on clinical co-development. Jayson has more than 10 years’ experience in venture…
Leading pharmaceutical and biotech product development consultancy Boyds has further strengthened its clinical operations offering with the appointment of Pippa Bjaaland as a Senior Clinical Research Associate (CRA), as part of an ongoing recruitment drive to grow in-house CRA expertise.
Pippa brings more than five years’ industry experience in clinical operations and joins Boyds from Syneos Health where she was a Senior CRA working on Phase II-IV studies, primarily in oncology. Prior to this, she worked as an in-house CRA at PRA Health Sciences.
Pippa holds a BSc in Psychology from the…
Marie Curie, née Maria Sklodowska, was born in Warsaw on November 7, 1867. She died July 4th 1934.
I could read about this Polish-born French scientist, famous for her work on radioactivity and twice a winner of the Nobel Prize. for. hours! I have referenced her in several of my blog posts already. With Henri Becquerel and her husband, Pierre Curie, she was awarded the 1903 Nobel Prize for Physics. She was later the sole winner of the 1911 Nobel Prize for Chemistry.
She was the first woman to win a Nobel Prize, and she is the first person and only woman to win the award in two different…
A busy month ahead for the Virtual Innovation Centre with two workshops discussing important topics for those Life Science companies becoming more active deal makers:
Growing with Underlying Principles of Drug Development in Mind on 18 November 11.30–12.30 is for early stage companies who need to show their understanding of the underlying principles of drug
development to their stakeholders and ensure they know how to evolve them as the company grows.
In collaboration with
Anatomy of a Research Collaboration Agreement to provide a review of the…
LONDON and CAMBRIDGE, Mass., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, and Blackstone Life Sciences today announced that the two companies have entered into a strategic collaboration and financing agreement under which funds managed by Blackstone (NYSE: BX) will provide up to $250 million in equity and product financing to support Autolus’ advancement of its CD19 CAR T cell investigational therapy product candidate, obecabtagene autoleucel (obe-cel), as well as…
Cambridge, UK, 8th November 2021: Chesterford Research Park is delighted to announce the expansion of existing occupier, CellCentric, within the Mansion House at the heart of the Park. The clinical stage biotechnology company focused on the development of a novel drug for specific cancers has renewed its current lease for Suite 3 in the 19th Century converted manor house, whilst at the same time expanding into Suite 4 within the same building.
Having secured $33m in funding from Morningside Venture Investments at the end of 2020, clinical trials for CellCentric’s novel drug CCS1477 have been…
CAMBRIDGE, UK, 5 November 2021 - today bit.bio announces the first close of their Series B financing of $103 million. New and existing institutional and strategic investors in the Series B round, thus far, include Arch Ventures, Charles River Laboratories, Foresite Capital, National Resilience, Inc. (Resilience), Metaplanet, Puhua Capital and Tencent.
The funding will accelerate the clinical development of the company’s proprietary cell coding technology opti-oxTM - a breakthrough gene engineering approach that enables unlimited batches of any human cell to be manufactured consistently…
Marks & Clerk, one of the world’s leading intellectual property (IP) law firms, has announced the promotion of Andrea Williams to Partner and the appointment of Senior Associate David Kemp to the Cambridge team, transferring from the London office. Both attorneys are part of the firm’s market-leading UK teams, with Andrea specialising in patents in the biotechnology field and David advising on all aspects of UK, EUTM and international trade mark law and practice. “I am delighted to announce the promotion of Andrea Williams to Partner, and welcome David Kemp to Cambridge. The attorneys in…
Arecor Therapeutics plc
(“Arecor” or the “Group”)
ARECOR ANNOUNCES AN EXCLUSIVE FORMULATION STUDY COLLABORATION WITH
A LEADING GLOBAL MEDICAL PRODUCTS COMPANY TO DEVELOP A STABLE READY TO ADMINISTER PRODUCT
Cambridge, UK, 1 November 2021: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today’s therapies to enable healthier lives, today announces that it has signed an exclusive formulation study collaboration with a leading global medical products company.
Under the terms of the agreement, Arecor will use its proprietary formulation technology platform, Arestat™, to…